Business
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, for the treatment of advanced malignant solid tumors. JSKN027 is the company's fifth ADC candidate entering clinical development, as well as the world's first PD-L1/ VEGFR2 bispecific ADC to advance into clinical trials.
About this update from Alphamab Oncology
[{"type":"text","content":"SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, for the treatment of advanced malignant solid tumors. JSKN027 is the company's fifth ADC candidate entering clinical development, as well as the world's first PD-L1/ VEGFR2 bispecific ADC to advance into clinical trials.","length":550,"tagName":"p"},{"type":"text","content":"As the global burden of malignant tumors continues to rise, there is an urgent clinical need for more effective and innovative therapies applicable across various tumor types. PD-L1 is a key molecule in regulating immune responses, and VEGFR2 is a core signaling hub in tumor angiogenesis. Within the immunosuppressive microenvironment of various solid tumors, the VEGF/VEGFR signaling pathway and the PD-1/PD-L1 axis exhibit a synergistic interplay, collectively driving immune evasion and providing a new strategy for dual-target therapy. JSKN027 is an innovative bispecific ADC designed based on this synergistic mechanism. By leveraging glycan-specific conjugation technology, it precisely links its cleavable linker and topoisomerase I inhibitor payload to the antibody's Fc region. This design confers multiple mechanisms of action, including targeted chemotherapy, anti-angiogenesis and immunotherapy. It is expected to synergistically enhance antitumor efficacy and overcome therapeutic resistance, offering a promising treatment strategy across solid tumors.","length":1071,"tagName":"p"},{"type":"text","content":"JSKN027-101 is an open-label, multi-center, Phase I clinical study, including dose-escalation and dose-expansion phases. This study aims to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and antitumor activity of JSKN027 in patients with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).","length":391,"tagName":"p"},{"type":"text","content":"About JSKN027","length":13,"tagName":"p"},{"type":"text","content":"JSKN027 is a first-in-class bispecific ADC designed to co-engage PD-L1 and VEGFR2. By leveraging glycan-specific conjugat...